The firms will use Resolution's ctDx liquid biopsy technology to find non-small cell lung cancer patients who may benefit from Mirati's KRAS G12C inhibitor therapy.
Sema4 will use its next-generation sequencing testing services to identify patients with solid tumors harboring NRG1 fusions for Merus' Phase I/II drug trial.
Oncocyte will receive upfront cash payments after transferring and installing DetermaRx, in addition to certain tests after it achieves inclusion in the US Comprehensive Cancer Network.
The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.
The firm will scale US-based testing capacity for its LiquidHallmark liquid biopsy assay, which uses amplicon-based technology to detect cancer-related mutations.
Ceres plans to develop its Nanotrap technology to isolate undetectable levels of circulating tumor DNA in blood samples from non-small cell lung cancer patients.
The B44 supertype is associated with improved survival in melanoma patients treated with immunotherapy, but less so in NSCLC patients, due to mutational differences.